FDA Should Be More Specific on Postmarketing Requirement Triggers

Stakeholders are telling the FDA that a July draft guidance on postmarketing studies should have described the safety signals the agency uses to determine that a postmarket clinical trial or study will be required. PhRMA says in comments posted on the FDA’s website that a final guidance also should outline the types of risks that would prompt the FDA to require postmarketing studies and clinical trials.
Drug Industry Daily